narcolepsy
Neurology · 2008–2022
No submission for this condition has carried consumer input, including the 3 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| modafinil, armodafinil First-line treatment of patients with narcolepsy (with and without cataplexy). | May 2022 | Recommended | no section in document |
| modafinil; armodafinil Treatment of narcolepsy, including improvement of wakefulness in patients with excessive daytime sleepiness associated with narcolepsy, and adjunct to CPAP in… | Jul 2020 | Noted | none received |
| armodafinil Treatment of excessive daytime sleepiness associated with narcolepsy. | Nov 2015 | Not recommended | none received |
| modafinil First-line treatment of narcolepsy in patients with excessive daytime sleepiness and either a definite history of cataplexy, mean sleep latency ≤10 minutes on… | Nov 2008 | Recommended | no section in document |
What the PBS pays
$26M in government benefit over 2024–25, across 166,086 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| modafinil, armodafinil | $8.8M |
| modafinil; armodafinil | $8.8M |
| armodafinil | $6.6M |
| modafinil | $2.2M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| solriamfetolSolriamfetol for treating excessive daytime sleepiness caused by narcolepsy | TA758 | recommended restricted | 2022-01 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| dexamfetamineAPO-DEXAMFETAMINE dexamfetamine sulfate 5 mg tablets blister packs | 1991 | 13 |
| sodium oxybateSODIUM OXYBATE-REACH sodium oxybate 500 mg/mL oral solution bottle | 2026 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.